336 related articles for article (PubMed ID: 29208938)
21. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
22. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
23. Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.
Meyers DE; Wang AA; Thirukkumaran CM; Morris DG
Front Oncol; 2017; 7():114. PubMed ID: 28634571
[TBL] [Abstract][Full Text] [Related]
24. Reovirus modulates autophagy during oncolysis of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Autophagy; 2013 Mar; 9(3):413-4. PubMed ID: 23322106
[TBL] [Abstract][Full Text] [Related]
25. Immunopathogenesis and immunotherapy of multiple myeloma.
Tamura H
Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cejalvo JM; Falato C; Villanueva L; Tolosa P; González X; Pascal M; Canes J; Gavilá J; Manso L; Pascual T; Prat A; Salvador F
Cancer Treat Rev; 2022 May; 106():102392. PubMed ID: 35436729
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.
Bourgeois-Daigneault MC; Roy DG; Aitken AS; El Sayes N; Martin NT; Varette O; Falls T; St-Germain LE; Pelin A; Lichty BD; Stojdl DF; Ungerechts G; Diallo JS; Bell JC
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298865
[TBL] [Abstract][Full Text] [Related]
29. Tumour vasculature: Friend or foe of oncolytic viruses?
Santry LA; van Vloten JP; Knapp JP; Matuszewska K; McAusland TM; Minott JA; Mould RC; Stegelmeier AA; Major PP; Wootton SK; Petrik JJ; Bridle BW
Cytokine Growth Factor Rev; 2020 Dec; 56():69-82. PubMed ID: 32893095
[TBL] [Abstract][Full Text] [Related]
30. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
[TBL] [Abstract][Full Text] [Related]
31. Thunder and lightning: immunotherapy and oncolytic viruses collide.
Melcher A; Parato K; Rooney CM; Bell JC
Mol Ther; 2011 Jun; 19(6):1008-16. PubMed ID: 21505424
[TBL] [Abstract][Full Text] [Related]
32. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
33. Evolution of oncolytic viruses: novel strategies for cancer treatment.
Atherton MJ; Lichty BD
Immunotherapy; 2013 Nov; 5(11):1191-206. PubMed ID: 24188674
[TBL] [Abstract][Full Text] [Related]
34. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
35. Virotherapy Research in Germany: From Engineering to Translation.
Ungerechts G; Engeland CE; Buchholz CJ; Eberle J; Fechner H; Geletneky K; Holm PS; Kreppel F; Kühnel F; Lang KS; Leber MF; Marchini A; Moehler M; Mühlebach MD; Rommelaere J; Springfeld C; Lauer UM; Nettelbeck DM
Hum Gene Ther; 2017 Oct; 28(10):800-819. PubMed ID: 28870120
[TBL] [Abstract][Full Text] [Related]
36. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic virotherapy for urological cancers.
Delwar Z; Zhang K; Rennie PS; Jia W
Nat Rev Urol; 2016 Jun; 13(6):334-52. PubMed ID: 27215429
[TBL] [Abstract][Full Text] [Related]
38. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
39. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
